“This study shows that Liposomal Blend is a vehicle with the ability to enhance the anti-aging properties of the ingredients within the facial serum by facilitating its delivery into the underlying layers of the skin.”
The study developed a novel microfluidic approach to co-encapsulate NMN and an anticancer drug, honokiol (HNK), in liposomes and established a new HPLC method for NMN encapsulation quantification.
This study evaluated the safety and effects of high-dose (3,000 mg) Nicotinamide Riboside (NR) supplementation in patients with Parkinson’s Disease (PD).
This study showed that NR (1 g/day) for 10 weeks is safe in adults with MCI and effectively increased blood levels of NAD+.
New research on NAD+ metabolism, NMN supplementation, and mitochondrial NAD+ levels was presented at the esteemed longevity conference, the Aging Research and Drug Discovery (ARDD) Meeting.
A recent systematic review evaluated ten studies with NAD+ precursors for efficacy and safety.